New hope for ovarian cancer patients resistant to PARP inhibitors
NCT ID NCT03579316
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests a drug called adavosertib, given alone or with olaparib, in women with ovarian, fallopian tube, or peritoneal cancer that has returned and stopped responding to PARP inhibitors. The goal is to see if these drugs can shrink tumors or stop them from growing. About 96 women will take part in this phase 2 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- Cancer drug combo tested for rare gene mutation – but trial stopped early
- New targeted therapy shows promise for Tough-to-Treat ovarian cancer
- Engineered immune cells target Hard-to-Treat ovarian cancer
- New combo therapy aims to control ovarian cancer and reduce painful fluid buildup